{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:38:06Z","timestamp":1781937486392,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ecl.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T01:41:37Z","timestamp":1663983697000},"page":"691-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating Patient-Reported Outcomes in Cushing\u2019s Syndrome"],"prefix":"10.1016","volume":"51","author":[{"given":"Namrata","family":"Gumaste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadeen Christi","family":"Cheesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib1","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing's syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0958-4","article-title":"Illustration of patient-reported outcome challenges and solutions in rare diseases: A systematic review in Cushing's syndrome","volume":"13","author":"Knoble","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ecl.2022.05.002_bib3","first-page":"61","article-title":"Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"issue":"4","key":"10.1016\/j.ecl.2022.05.002_bib4","doi-asserted-by":"crossref","first-page":"M33","DOI":"10.1530\/EJE-15-0464","article-title":"Cushing's syndrome: Update on signs, symptoms and biochemical screening","volume":"173","author":"Nieman","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2022.05.002_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-017-0735-z","article-title":"Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management","volume":"77","author":"Santos","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing's syndrome: 2-Year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"9\u201310","key":"10.1016\/j.ecl.2022.05.002_bib7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1159\/000506809","article-title":"Patient-Centered Outcomes with Pituitary and Parasellar Disease","volume":"110","author":"Webb","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2022.05.002_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4064370","article-title":"Neuropsychological and Emotional Functioning in Patients with Cushing's Syndrome","volume":"2020","author":"Na","year":"2020","journal-title":"Behav Neurol"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00006842-198102000-00002","article-title":"Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels","volume":"43","author":"Starkman","year":"1981","journal-title":"Psychosom Med"},{"issue":"4","key":"10.1016\/j.ecl.2022.05.002_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2007-1014405","article-title":"Psychiatric phenomenology in Cushing's disease","volume":"25","author":"Loosen","year":"1992","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.ecl.2022.05.002_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/qjmed\/89.7.543","article-title":"Psychiatric aspects of Cushing's syndrome","volume":"89","author":"Kelly","year":"1996","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.ecl.2022.05.002_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/EJE-14-0371","article-title":"Small cerebellar cortex volume in patients with active Cushing's syndrome","volume":"171","author":"Santos","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2022.05.002_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11102-013-0484-2","article-title":"Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: What have we learnt?","volume":"17","author":"Badia","year":"2014","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.ecl.2022.05.002_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-Month Phase 3 Study of Pasireotide in Cushing's Disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-13-1013","article-title":"Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease","volume":"171","author":"Webb","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib16","first-page":"34","article-title":"Cushing's disease - Quality of life, recurrence and long-term morbidity","volume":"11","author":"Huguet","year":"2015","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.ecl.2022.05.002_bib17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fendo.2019.00862","article-title":"Quality of Life in Patients With Cushing's Disease","volume":"10","author":"Santos","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 11","key":"10.1016\/j.ecl.2022.05.002_bib18","first-page":"S383","volume":"63","author":"Busija","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ecl.2022.05.002_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/IJGM.S258953","article-title":"Comparison of SF-36 and WHOQoL-BREF in Measuring Quality of Life in Patients with Type 2 Diabetes","volume":"13","author":"Abbasi-Ghahramanloo","year":"2020","journal-title":"Int J Gen Med"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib20","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"Quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2265.2011.04191.x","article-title":"The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part I: Construction and psychometric properties","volume":"76","author":"Milian","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2022.05.002_bib22","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1002\/acr.20561","article-title":"Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/cen.12521","article-title":"Predictors of quality of life in 102 patients with treated Cushing's disease","volume":"82","author":"Carluccio","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"15","key":"10.1016\/j.ecl.2022.05.002_bib24","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1017\/S0033291715001270","article-title":"Minimal clinically important difference on the Beck Depression Inventory--II according to the patient's perspective","volume":"45","author":"Button","year":"2015","journal-title":"Psychol Med"},{"issue":"Suppl 11","key":"10.1016\/j.ecl.2022.05.002_bib25","first-page":"S263","volume":"63","author":"Hewlett","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ecl.2022.05.002_bib26","first-page":"287","article-title":"Sexual function in women with cushing\u2019s syndrome: A controlled study","volume":"44","author":"Keskin","year":"2018","journal-title":"Turkish J Urol"},{"key":"10.1016\/j.ecl.2022.05.002_bib27","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1002\/acr.20544","article-title":"Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI)","volume":"63","author":"Omachi","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.ecl.2022.05.002_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2022.05.002_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40271-013-0012-5","article-title":"Psychometric evaluation of the Cushing's Quality-of-Life questionnaire","volume":"6","author":"Nelson","year":"2013","journal-title":"The patient"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib30","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2022.05.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2015-007953","article-title":"Minimally important difference estimates and methods: A protocol","volume":"5","author":"Johnston","year":"2015","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/EJE-12-0325","article-title":"Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice","volume":"167","author":"Santos","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2265.2011.04280.x","article-title":"The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part II: Normative data from 1784 healthy people","volume":"76","author":"Milian","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2022.05.002_bib34","doi-asserted-by":"crossref","first-page":"bvab109","DOI":"10.1210\/jendso\/bvab109","article-title":"Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome","volume":"5","author":"Acree","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ando.2018.03.007","article-title":"Quality of Life in Cushing's disease: A long term issue?","volume":"79","author":"Webb","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib36","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1210\/jc.2004-1375","article-title":"Quality of life in patients after long-term biochemical cure of Cushing's disease","volume":"90","author":"van Aken","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2022.05.002_bib37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-11-0307","article-title":"Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome","volume":"165","author":"Tiemensma","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000355622","article-title":"Tuebingen CD-25 Is a Sensitive Tool to Investigate Health-Related Quality of Life in Cushing's Disease Patients in the Course of the Disease","volume":"98","author":"Milian","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"1\u20132","key":"10.1016\/j.ecl.2022.05.002_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000431022","article-title":"Validation of the Tuebingen CD-25 Inventory as a Measure of Postoperative Health-Related Quality of Life in Patients Treated for Cushing's Disease","volume":"102","author":"Milian","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s11102-016-0750-1","article-title":"Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease","volume":"19","author":"Siegel","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2022.05.002_bib41","article-title":"Patients' Perception On Clinical Outcome And Quality Of Life After A Diagnosis Of Cushing Syndrome","volume":"22","author":"Papoian","year":"2015","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.ecl.2022.05.002_bib42","first-page":"2647","article-title":"Risk factors and long-term outcome in pituitary-dependent Cushing's disease","volume":"81","author":"Sonino","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib43","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jc.2012-2893","article-title":"Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients","volume":"98","author":"Lambert","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2022.05.002_bib44","doi-asserted-by":"crossref","first-page":"D9","DOI":"10.1530\/EJE-19-0092","article-title":"Radiotherapy as a tool for the treatment of Cushing's disease","volume":"180","author":"Castinetti","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.13600","article-title":"Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN","volume":"88","author":"Valassi","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.ecl.2022.05.002_bib46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/jc.2005-1058","article-title":"Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission","volume":"91","author":"Lindsay","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2022.05.002_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121884","article-title":"Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up","volume":"11","author":"Kessel","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2022.05.002_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2022.05.002_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00436","article-title":"Safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: Results from an open-label, multicenter, single-arm, multinational, expanded-access study","volume":"10","author":"Fleseriu","year":"2019","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2022.05.002_bib51","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","article-title":"Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study","volume":"43","author":"Lacroix","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.ecl.2022.05.002_bib52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11102-020-01103-6","article-title":"Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing\u2019s syndrome","volume":"24","author":"Geer","year":"2021","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib54","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.05.002_bib55","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/173653","article-title":"Mental Fatigue and Executive Dysfunction in Patients with Cushing's Syndrome in Remission","volume":"2015","author":"Papakokkinou","year":"2015","journal-title":"Behav Neurol"},{"issue":"9","key":"10.1016\/j.ecl.2022.05.002_bib56","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-018-1664-7","article-title":"Lack of functional remission in Cushing's syndrome","volume":"61","author":"Vermalle","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0035-1569340","article-title":"Health-related Quality of Life in Patients After Treatment of Cushing's Disease","volume":"124","author":"Nader","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2022.05.002_bib59","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-12-0308","article-title":"Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism?","volume":"167","author":"Wagenmakers","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2022.05.002_bib60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0306-4530(01)00059-2","article-title":"Persistent cognitive impairment following surgical treatment of Cushing's syndrome","volume":"27","author":"Forget","year":"2002","journal-title":"Psychoneuroendocrinology"},{"issue":"9996","key":"10.1016\/j.ecl.2022.05.002_bib61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.05.002_bib62","doi-asserted-by":"crossref","first-page":"675310","DOI":"10.5402\/2012\/675310","article-title":"Long-term health-related quality of life of surgically treated pituitary adenoma patients: a descriptive study","volume":"2012","author":"Raappana","year":"2012","journal-title":"ISRN Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib63","first-page":"117","article-title":"Incidence and late prognosis of cushing's syndrome: a population-based study","volume":"86","author":"Lindholm","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2022.05.002_bib64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2265.2008.03288.x","article-title":"Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas","volume":"69","author":"van der Klaauw","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ando.2018.01.002","article-title":"Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options","volume":"80","author":"Sarkis","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"10.1016\/j.ecl.2022.05.002_bib66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1067\/msy.2002.128482","article-title":"Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease","volume":"132","author":"Hawn","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.ecl.2022.05.002_bib67","doi-asserted-by":"crossref","first-page":"9014768","DOI":"10.1155\/2018\/9014768","article-title":"Support Needs of Patients with Cushing's Disease and Cushing's Syndrome: Results of a Survey Conducted in Germany and the USA","volume":"2018","author":"Kreitschmann-Andermahr","year":"2018","journal-title":"Int J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib68","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12020-015-0737-0","article-title":"A\u00a0specific nursing educational program in patients with Cushing's syndrome","volume":"53","author":"Mart\u00ednez-Mombl\u00e1n","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2022.05.002_bib69","doi-asserted-by":"crossref","first-page":"101505","DOI":"10.1016\/j.beem.2021.101505","article-title":"Quality of life in Cushing's syndrome","volume":"35","author":"Bride","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:47:33Z","timestamp":1760176053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0889852922000500"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.05.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Patient-Reported Outcomes in Cushing\u2019s Syndrome","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}